The recently reported gain of function mutations in signal transduction molecules has remarkably increased our knowledge about the molecular genetics of myeloproliferative neoplasms (MPN) [1] . JAK2 mutations occur in most patients with polycythemia vera (PV) and in about half of the patients with essential thrombocythemia (ET) JAK2 V617F and MPL W515L/K mutations have been reported in approximately 50% and 5% of the patients with essential thrombocythemia (ET), respectively. We investigated the frequency of MPL W515L/K mutations in a series of consecutive patients with ET and post-essential thrombocythemia myelofibrosis (post-ET MF). The study subjects were 63 patients diagnosed either with ET (N=59) or post-ET MF (N=4) at our institution between June 2006 and February 2010. Among them, 35 (55.6%) had the JAK2 V617F mutation. MPL W515L/K mutations were detected by direct sequencing analyses of exon 10, and 2 patients were found to harbor the following MPL mutations: W515L in 1 patient with ET and W515K in 1 patient with post-ET MF. Neither of the patients had the JAK2 V617F mutation. The frequencies of the MPL W515L/K and JAK2 V617F-negative mutations in our subjects with ET/post-ET MF were 3.2% (2/63) and 7.1% (2/28), respectively. This is the first study to report the frequency of JAK2 V617F and MPL W515L/K mutations in Korean patients with ET/post-ET MF. (Korean J Lab Med 2010;30:474-6) 
in most patients with polycythemia vera (PV) and in about half of the patients with essential thrombocythemia (ET) [2] . Missense mutations in the MPL gene, which encodes the thrombopoietin receptor MIM 159530 have also been reported in a small proportion (19%) of patients with ET and primary myelofibrosis [3] [4] [5] [6] . MPL mutations usually affect the W515 residue in exon 10 [3, 7] . We investigat- are the 2 most frequent MPL mutations in ET, each accounting for 60-75% and 16-40%, respectively [3, 6, 7] .
Unlike MPN with JAK2 mutations, only limited studies have been reported on genotype-phenotype correlations in MPL mutations [3, 5, 6] . As for the type of the mutation, while the W515L mutation is consistently from c.1544G>T, 2 different mutations have been reported to cause W515K, c.1543_1544TG>AA and c.1543_1545TGG>AAA [3] . Interestingly, c.1543_1544TG>AA was reported in patients with both ET and idiopathic myelofibrosis (IMF), while c.1543_1545TGG>AAA was described only in IMF [3] . As for the mutant allele burden, W515K was reported more frequently to be homozygous than W515L, particularly in ET [3] [4] [5] [6] . Lastly, a significantly younger age at onset was reported in W515K than in W515L, although controversies still exist on this correlation [3, 6] . In our 2 Kore- 
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